fluvoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1230	54739-18-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fluvoxamine fluvoxamine maleate depromel	A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19. Molecular weight: 318.34 Formula: C15H21F3N2O2 CLOGP: 2.77 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 56.84 ALOGS: -4.64 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fluvoxamine
fluvoxamine maleate
depromel

A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.

Molecular weight: 318.34
Formula: C15H21F3N2O2
CLOGP: 2.77
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 56.84
ALOGS: -4.64
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	14.87 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	53 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	31.95 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 5, 1994	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	220.90	19.82	178	5311	199443	50400192
Serotonin syndrome	129.48	19.82	60	5429	24653	50574982
Myoglobin urine present	128.28	19.82	24	5465	366	50599269
Intentional self-injury	111.46	19.82	53	5436	23059	50576576
Suicide attempt	100.16	19.82	65	5424	51667	50547968
Intentional overdose	86.76	19.82	64	5425	62440	50537195
Blood creatine phosphokinase increased	76.55	19.82	43	5446	26324	50573311
Toxicity to various agents	74.84	19.82	103	5386	212396	50387239
Toxic encephalopathy	68.97	19.82	25	5464	5490	50594145
Neuroleptic malignant syndrome	67.67	19.82	30	5459	11100	50588535
Amylase increased	65.62	19.82	24	5465	5406	50594229
Troponin increased	56.26	19.82	24	5465	8094	50591541
Drug abuse	48.76	19.82	45	5444	59801	50539834
Suicidal ideation	47.77	19.82	43	5446	55342	50544293
Blood lactate dehydrogenase increased	46.42	19.82	28	5461	19534	50580101
Blood potassium increased	45.57	19.82	26	5463	16372	50583263
Somnolence	45.49	19.82	69	5420	154916	50444719
Oscillopsia	42.21	19.82	8	5481	131	50599504
Schizophrenia	41.96	19.82	19	5470	7378	50592257
Mydriasis	41.14	19.82	21	5468	10606	50589029
Drug level increased	34.29	19.82	23	5466	19245	50580390
Galactorrhoea	32.55	19.82	13	5476	3710	50595925
Anxiety	31.09	19.82	63	5426	177543	50422092
Completed suicide	30.85	19.82	53	5436	131836	50467799
Alanine aminotransferase increased	28.27	19.82	41	5448	88318	50511317
Electrocardiogram QT prolonged	27.58	19.82	31	5458	51855	50547780
Obsessive-compulsive disorder	26.92	19.82	11	5478	3329	50596306
Overdose	25.88	19.82	42	5447	99685	50499950
Torsade de pointes	25.67	19.82	16	5473	11819	50587816
Tremor	25.34	19.82	45	5444	114858	50484777
Agitation	25.19	19.82	30	5459	53354	50546281
Sopor	24.53	19.82	19	5470	19860	50579775
Personality disorder	24.18	19.82	11	5478	4313	50595322
Alice in wonderland syndrome	23.85	19.82	4	5485	31	50599604
Drug screen false positive	23.66	19.82	7	5482	812	50598823
Akinesia	23.34	19.82	8	5481	1491	50598144
Restlessness	22.58	19.82	20	5469	25153	50574482
Anaemia folate deficiency	22.51	19.82	5	5484	184	50599451
Congestive cardiomyopathy	21.63	19.82	11	5478	5507	50594128
Mental disorder	20.79	19.82	18	5471	21973	50577662
Miosis	20.24	19.82	11	5478	6299	50593336

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Loss of libido	200.81	22.00	52	5197	2244	29567034
Apathy	150.08	22.00	52	5197	6119	29563159
Drug interaction	135.31	22.00	170	5079	197215	29372063
Psychotic disorder	129.73	22.00	66	5183	20288	29548990
Schizophrenia	128.14	22.00	47	5202	6518	29562760
Suicidal ideation	116.55	22.00	74	5175	34642	29534636
Serotonin syndrome	95.02	22.00	51	5198	17461	29551817
Persecutory delusion	80.10	22.00	25	5224	2116	29567162
Neuroleptic malignant syndrome	76.48	22.00	43	5206	16105	29553173
Encephalitis toxic	70.35	22.00	15	5234	272	29569006
Social avoidant behaviour	64.63	22.00	23	5226	2919	29566359
Weight increased	63.58	22.00	73	5176	76594	29492684
Sedation	63.10	22.00	39	5210	17366	29551912
Suicide attempt	57.61	22.00	48	5201	34062	29535216
Intentional overdose	52.54	22.00	48	5201	38480	29530798
Catatonia	51.94	22.00	22	5227	4446	29564832
Depression	51.17	22.00	69	5180	85078	29484200
Overdose	48.44	22.00	65	5184	79754	29489524
Salivary hypersecretion	47.07	22.00	24	5225	7385	29561893
Delirium	45.91	22.00	45	5204	39352	29529926
Antipsychotic drug level increased	44.57	22.00	18	5231	3225	29566053
Mental impairment	39.65	22.00	23	5226	9118	29560160
Drug level increased	39.31	22.00	30	5219	18757	29550521
Cardiac dysfunction	39.21	22.00	14	5235	1793	29567485
Aggression	38.46	22.00	39	5210	35502	29533776
Sopor	38.35	22.00	24	5225	10910	29558368
Sexual relationship change	37.77	22.00	6	5243	17	29569261
Toxicity to various agents	37.60	22.00	90	5159	173571	29395707
Enuresis	37.26	22.00	14	5235	2070	29567208
Completed suicide	34.12	22.00	59	5190	90187	29479091
Hanging	33.25	22.00	7	5242	119	29569159
Obsessive-compulsive disorder	32.52	22.00	16	5233	4560	29564718
Respiratory fatigue	30.93	22.00	6	5243	66	29569212
Obsessive thoughts	30.73	22.00	9	5240	613	29568665
Coma scale abnormal	30.37	22.00	14	5235	3455	29565823
Cyclothymic disorder	29.59	22.00	6	5243	84	29569194
Antipsychotic drug level above therapeutic	29.56	22.00	10	5239	1091	29568187
Premature ejaculation	27.58	22.00	6	5243	120	29569158
Neonatal behavioural syndrome	27.48	22.00	6	5243	122	29569156
Anxiety	27.41	22.00	52	5197	85313	29483965
Akathisia	26.71	22.00	16	5233	6726	29562552
Distributive shock	26.65	22.00	9	5240	976	29568302
Bradycardia	26.23	22.00	44	5205	65585	29503693
Motor developmental delay	25.91	22.00	8	5241	652	29568626
Genital pain	25.06	22.00	6	5243	186	29569092
Orthostatic hypotension	24.77	22.00	25	5224	22604	29546674
Tic	24.58	22.00	10	5239	1825	29567453
Genital hypoaesthesia	24.47	22.00	6	5243	206	29569072
Brain injury	24.25	22.00	14	5235	5498	29563780
Somnolence	23.94	22.00	52	5197	93903	29475375
Heat stroke	23.40	22.00	8	5241	901	29568377
Agitation	22.66	22.00	36	5213	51268	29518010
Tardive dyskinesia	22.19	22.00	13	5236	5245	29564033
Hypothermia	22.11	22.00	16	5233	9223	29560055

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	291.86	18.06	305	8894	361778	64127755
Serotonin syndrome	211.82	18.06	106	9093	39176	64450357
Intentional overdose	133.28	18.06	107	9092	89837	64399696
Suicide attempt	132.71	18.06	97	9102	70910	64418623
Neuroleptic malignant syndrome	113.13	18.06	60	9139	24936	64464597
Intentional self-injury	112.81	18.06	63	9136	28981	64460552
Myoglobin urine present	111.79	18.06	24	9175	566	64488967
Toxicity to various agents	99.32	18.06	182	9017	363331	64126202
Suicidal ideation	96.05	18.06	78	9121	66464	64423069
Loss of libido	95.66	18.06	28	9171	2376	64487157
Apathy	77.71	18.06	36	9163	11196	64478337
Blood creatine phosphokinase increased	74.85	18.06	64	9135	58494	64431039
Psychotic disorder	73.19	18.06	51	9148	34527	64455006
Schizophrenia	68.67	18.06	33	9166	11135	64478398
Encephalitis toxic	67.55	18.06	14	9185	277	64489256
Catatonia	67.37	18.06	29	9170	7591	64481942
Overdose	62.36	18.06	94	9105	159472	64330061
Completed suicide	59.39	18.06	111	9088	224303	64265230
Somnolence	56.73	18.06	103	9096	203542	64285991
Sopor	54.16	18.06	40	9159	29621	64459912
Troponin increased	53.31	18.06	31	9168	15368	64474165
Drug level increased	51.24	18.06	41	9158	34155	64455378
Anxiety	47.19	18.06	95	9104	202554	64286979
Sedation	46.32	18.06	42	9157	41420	64448113
Toxic encephalopathy	45.63	18.06	24	9175	9791	64479742
Obsessive-compulsive disorder	44.78	18.06	19	9180	4799	64484734
Salivary hypersecretion	43.56	18.06	25	9174	12088	64477445
Amylase increased	43.09	18.06	23	9176	9662	64479871
Tremor	42.55	18.06	76	9123	148154	64341379
Drug abuse	42.07	18.06	71	9128	132303	64357230
Agitation	41.73	18.06	57	9142	88310	64401223
Aggression	40.58	18.06	41	9158	46191	64443342
Oscillopsia	37.79	18.06	8	9191	176	64489357
Obsessive thoughts	36.77	18.06	11	9188	1006	64488527
Akathisia	36.76	18.06	22	9177	11488	64478045
Enuresis	36.26	18.06	14	9185	2776	64486757
Hanging	35.79	18.06	7	9192	102	64489431
Mental impairment	34.32	18.06	24	9175	16319	64473214
Galactorrhoea	34.32	18.06	14	9185	3205	64486328
Sexual relationship change	32.88	18.06	5	9194	13	64489520
Cardiac dysfunction	31.38	18.06	13	9186	3093	64486440
Cyclothymic disorder	31.11	18.06	7	9192	206	64489327
Antipsychotic drug level increased	31.09	18.06	15	9184	5100	64484433
Blood potassium increased	30.36	18.06	27	9172	25953	64463580
Mydriasis	28.74	18.06	21	9178	15291	64474242
Blood lactate dehydrogenase increased	28.41	18.06	29	9170	33049	64456484
Dyspnoea	28.03	18.06	37	9162	718637	63770896
Rhabdomyolysis	27.55	18.06	48	9151	91678	64397855
Delirium	27.31	18.06	41	9158	69153	64420380
Gaze palsy	26.87	18.06	11	9188	2539	64486994
Antipsychotic drug level above therapeutic	26.56	18.06	10	9189	1851	64487682
Distributive shock	26.49	18.06	10	9189	1865	64487668
Extrapyramidal disorder	26.25	18.06	22	9177	19530	64470003
Semen volume decreased	26.24	18.06	5	9194	63	64489470
Premature ejaculation	26.02	18.06	5	9194	66	64489467
Respiratory fatigue	25.61	18.06	6	9193	212	64489321
Activation syndrome	24.31	18.06	6	9193	265	64489268
Pain	24.22	18.06	26	9173	553485	63936048
Inappropriate antidiuretic hormone secretion	23.76	18.06	22	9177	22267	64467266
Mania	23.27	18.06	19	9180	16267	64473266
Weight increased	23.20	18.06	75	9124	213273	64276260
Coma scale abnormal	22.62	18.06	14	9185	7760	64481773
Arthralgia	22.62	18.06	18	9181	442242	64047291
Orgasmic sensation decreased	21.93	18.06	4	9195	39	64489494
Brain injury	21.78	18.06	15	9184	9950	64479583
Acanthosis nigricans	21.76	18.06	5	9194	162	64489371
Genital hypoaesthesia	21.56	18.06	5	9194	169	64489364
Alice in wonderland syndrome	21.49	18.06	4	9195	44	64489489
Depressed level of consciousness	21.12	18.06	40	9159	81396	64408137
Parkinsonism	21.02	18.06	17	9182	14356	64475177
Restlessness	20.82	18.06	27	9172	39758	64449775
Orthostatic hypotension	20.33	18.06	29	9170	46709	64442824
Drug screen false positive	20.32	18.06	7	9192	1005	64488528
Bradycardia	20.19	18.06	49	9150	118170	64371363
Anaemia folate deficiency	19.75	18.06	5	9194	245	64489288
Myoclonus	19.74	18.06	21	9178	25097	64464436
Psychomotor skills impaired	19.59	18.06	10	9189	3835	64485698
Respiratory depression	19.13	18.06	20	9179	23423	64466110
Aspiration of gastric residual	18.74	18.06	3	9196	12	64489521
Altered state of consciousness	18.71	18.06	25	9174	37877	64451656
Akinesia	18.63	18.06	9	9190	3070	64486463
Negativism	18.19	18.06	6	9193	754	64488779
Electrocardiogram QT prolonged	18.15	18.06	37	9162	79411	64410122

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AB08	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Selective serotonin reuptake inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:50949	SSRI
FDA EPC	N0000175696	Serotonin Reuptake Inhibitor
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018687	Antidepressive Agents, Second-Generation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065689	Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017367	Serotonin Uptake Inhibitors
MeSH PA	D014149	Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Social phobia	indication	25501002	DOID:11257
Obsessive-compulsive disorder	indication	191736004	DOID:10933
Depressive disorder	off-label use	35489007
Posttraumatic stress disorder	off-label use	47505003	DOID:2055
Bipolar affective disorder, current episode depression	off-label use	191627008	DOID:3312
Suicidal thoughts	contraindication	6471006
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Upper gastrointestinal hemorrhage	contraindication	37372002
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Blood coagulation disorder	contraindication	64779008	DOID:1247
Epilepsy	contraindication	84757009	DOID:1826
Hyponatremia	contraindication	89627008
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Disease of liver	contraindication	235856003	DOID:409
Serotonin syndrome	contraindication	371089000
Breastfeeding (mother)	contraindication	413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	423629005
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.36	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	8.51	WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.95	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	8.84	CHEMBL
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		Ki	5.07	WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.44	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT	INHIBITOR	Ki	8.19	IUPHAR
Sigma non-opioid intracellular receptor 1	Membrane receptor		SGMR1_RAT		Ki	7.44	CHEMBL
Sigma intracellular receptor 2	Unclassified		SGMR2_RAT		Ki	5.07	CHEMBL

External reference:

ID	Source
4023976	VUID
N0000021981	NUI
D00824	KEGG_DRUG
61718-82-9	SECONDARY_CAS_RN
4020892	VANDF
4023976	VANDF
C0085228	UMLSCUI
CHEBI:5138	CHEBI
FVX	PDB_CHEM_ID
CHEMBL814	ChEMBL_ID
DB00176	DRUGBANK_ID
CHEMBL1409	ChEMBL_ID
D016666	MESH_DESCRIPTOR_UI
5324346	PUBCHEM_CID
7189	IUPHAR_LIGAND_ID
3879	INN_ID
O4L1XPO44W	UNII
203143	RXNORM
40916	MMSL
4758	MMSL
d03804	MMSL
003633	NDDF
003634	NDDF
116522003	SNOMEDCT_US
372905008	SNOMEDCT_US
96213009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2848	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	21 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2849	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	21 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1670	TABLET, FILM COATED	25 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1671	TABLET, FILM COATED	50 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1672	TABLET, FILM COATED	100 mg	ORAL	ANDA	34 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-175	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-176	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-270	TABLET	25 mg	ORAL	NDA	11 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-683	TABLET, COATED	50 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5988	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0164	TABLET	25 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0165	TABLET	50 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0166	TABLET	100 mg	ORAL	ANDA	32 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-158	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-159	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-160	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8018	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2337	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68151-0637	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-7219	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-7219	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-8175	TABLET	100 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	69452-182	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	22 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	69452-183	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	22 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1057	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1643	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1789	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1789	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3153	TABLET, FILM COATED	50 mg	ORAL	ANDA	33 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	71335-0264	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections